Publicaciones en las que colabora con Pascual Marco Vera (26)

2018

  1. Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU

    Revista Espanola de Cardiologia, Vol. 71, Núm. 7, pp. 553-564

2015

  1. Effects of body mass index on the lipid profile and biomarkers of inflammation and a fibrinolytic and Prothrombotic state

    Journal of Atherosclerosis and Thrombosis, Vol. 22, Núm. 6, pp. 610-617

2010

  1. The prognostic value of biomarkers after a premature myocardial infarction

    International Journal of Cardiology, Vol. 143, Núm. 3, pp. 249-254

2009

  1. Premature coronary artery disease in young (age < 45) subjects: Interactions of lipid profile, thrombophilic and haemostatic markers

    International Journal of Cardiology, Vol. 136, Núm. 2, pp. 222-225

2008

  1. Premature myocardial infarction: Clinical profile and angiographic findings

    International Journal of Cardiology, Vol. 126, Núm. 1, pp. 127-129

2004

  1. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation

    Heart, Vol. 90, Núm. 10, pp. 1162-1166

2003

  1. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation

    European Heart Journal, Vol. 24, Núm. 14, pp. 1373-1380

  2. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?

    Stroke, Vol. 34, Núm. 5, pp. 1181-1186

  3. The -1C>T mutation in the annexin A5 gene does not affect plasma levels of annexin A5 [2] (multiple letters)

    Blood

2002

  1. A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients

    Blood, Vol. 100, Núm. 6, pp. 2081-2086

  2. Annexin V levels in survivors of early myocardial

    Revista Espanola de Cardiologia, Vol. 55, Núm. 12, pp. 1230-1234

  3. Diurnal variation in the intensity of anticoagulation in atrial fibrillation (multiple letters) [2]

    Stroke

  4. Do protein Z levels influence the prothrombotic state in atrial fibrillation? [3]

    Thrombosis Research

  5. Prothrombin fragment F1 + 2 and von Willebrand factor levels and left ventricular systolic function. Peripheral versus intracardiac blood samples [8]

    International Journal of Cardiology

  6. The role of tissue plasminogen activator on the progression of the coronary disease [2]

    European Heart Journal

2001

  1. Thrombogenic and endothelial damage markers in patients withischemic systolic impairment

    Revista Espanola de Cardiologia, Vol. 54, Núm. 10, pp. 1155-1160

  2. Tissue factor/tissue factor pathway inhibitor system and long-term prognosis after acute myocardial infarction

    International Journal of Cardiology, Vol. 78, Núm. 2, pp. 115-119

2000

  1. Anticoagulant therapy modifies fibrinolytic dysfunction in chronic atrial fibrillation

    Haemostasis, Vol. 30, Núm. 4, pp. 219-224

  2. Effect of oral anticoagulant therapy on fibrinolysis parameters in chronic non-rheumatic atrial fibrillation

    Haematologica, Vol. 85, Núm. 7, pp. 778-780

1999

  1. Activador tisular del plasminógeno como factor pronóstico en pacientes con infarto de miocardio

    Revista Clinica Espanola, Vol. 199, Núm. 4, pp. 215-217